RTTNews BiotechCodex · 实盘不做把握 6/10
北京时间·🕒 发布 07-30 17:54:24时区推断·⟳ 抓取 07-30 18:00:26·⚡ 决策 07-31 01:30:07 +7h29m·88.8 天前
Haleon公布2026年上半年业绩，调整后利润增长但指引未上修且报告利润下滑
Haleon上半年收入£56.02亿、调整后EPS 10.3p略高于公司共识10.0p，但有机增长2.6%仅符合共识且全年3%-5%指引未上修。
📄 原文RTTNews Biotech↗ 原文
Supplier Of Advil, Haleon Reports Half-Year 2026 Results
Haleon plc (HLN.L), a consumer health company known for brands such as Advil, Sensodyne, Centrum, Panadol, and Voltaren…
不做 Haleon（HLN.US）
财报是调整后小幅好于共识、报告利润下滑和指引不变的混合信号；ADR已在盘中下跌消化，既没有追多的正向surprise，也未达到强空催化标准，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- Haleon发布2026年上半年业绩，确认调整后EPS增长12%、报告EPS下降4.5%，并维持全年3%-5%有机收入增长指引。
- RTTNews转述Haleon上半年业绩和资本开支、回购、股息信息，属于官方财报后的媒体扩散。
- 市场评论提到Haleon呼吸健康特别是亚太/中国疲弱，分析师认为有机增长偏弱、表现混合。市场反应:HLN.US在2026-07-30 17:28 UTC报价约10.0201美元，较前收跌2.53%。
关键理由
- Haleon上半年收入£56.02亿、调整后EPS 10.3p略高于公司共识10.0p，但有机增长2.6%仅符合共识且全年3%-5%指引未上修。
- 报告口径经营利润同比下降2.6%、报告EPS下降4.5%，主要受重组成本影响，叠加呼吸健康收入有机下降4.7%，解释了股价走弱但不是新的强空催化。
- HLN.US在美股盘中已跌约2.5%，当前信息从官方披露到现在已被LSE和NYSE消化，追空和抄底都缺少明确剩余edge。
主要风险
- 若后续管理层或卖方确认呼吸健康疲弱会拖累全年3%-5%有机增长指引，利空可能升级；但本次公司仍维持全年和中期指引。
- RTTNews稿中LSE价格口径疑似单位异常，执行判断以HLN.US实时报价和官方财报为准。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-07-30 · 影响 weakens
调整后EPS和调整后经营利润高于共识，全年指引未下修，削弱把本次事件作为强空催化的依据。
检索:Haleon H1 2026 consensus adjusted EPS guidance respiratory health weakness 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-07-30 · 影响 weakens
市场评论聚焦呼吸健康疲弱和有机增长质量，且ADR已下跌，削弱财报后反手做多。
检索:Haleon H1 2026 shares fall respiratory health organic growth analyst comments 原文 ↗
工具调用 · 历史记录,结果未知(1 种)
- stock_quote · 结果未知
原文全文
展开原文 · 2,541 字
Haleon plc (HLN.L), a consumer health company known for brands such as Advil, Sensodyne, Centrum, Panadol, and Voltaren, announced its unaudited financial results for the six months ended June 30, 2026.
Revenue Performance
Revenue for H1 2026 rose to £5,602 million, up 2.2% from £5,480 million in H1 2025. Organic revenue growth was 2.6%, compared to 3.2% in the prior year, reflecting balanced contributions from price and volume/mix.
Profitability
Adjusted gross profit increased to £3,728 million up 4.7% from £3,561 million in H1 2025, with adjusted gross margin expanding to 66.5%. Reported gross profit was £3,691 million, also up 4.7% year-on year.
Adjusted operating profit rose to £1,364 million, up 8.2% from £1,243 million in H1 2025. Adjusted operating margin improved to 24.3%, compared to 22.7% last year. Reported operating profit, however, declined to £1,172 million, down 2.6% from £1,203 million in H1 2025, impacted by restructuring costs.
Earnings
Adjusted diluted EPS climbed to 10.3p, up 12% from 9.2p in H1 2025. Reported diluted EPS fell to 8.5p, down 4.5% from 8.9p last year.
Cash Flow and Debt
Free cash flow improved to £769 million, compared to £734 million in H1 2025. Net cash flow from operating activities was £1,044 million, slightly higher than £1,027 million last year. Net debt/adjusted EBITDA stood at 2.5x in H1 2026, reflecting disciplined capital allocation.
Capital Allocation
Haleon announced approximately £240 million in capital investments for new manufacturing sites in China and India. The company completed £457 million of its planned £500 million share buyback program for 2026. An interim dividend of 2.4p per share was declared, up 9% from 2.2p in H1 2025.
Outlook
Haleon reaffirmed its FY 2026 guidance, expecting 3-5% organic revenue growth compared to £11,030 million achieved in FY2025 and high single-digit adjusted operating profit growth at constant currency.
Medium-term guidance remains at 4-6% annual organic revenue growth with continued gross margin expansion.
HLN.L has traded between £181.15 and £289.50 over the past year. The stock is currently trading at £228.30, down 9.01%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 30, 2026 04:24 ET The August 2026 FDA calendar features several important PDUFA decisions that could influence the biotech sector, healthcare innovation, and investor sentiment. In this video, we break down five major FDA decisions expected in August 2026, including the therapies, companies, and diseases under review:
Revenue Performance
Revenue for H1 2026 rose to £5,602 million, up 2.2% from £5,480 million in H1 2025. Organic revenue growth was 2.6%, compared to 3.2% in the prior year, reflecting balanced contributions from price and volume/mix.
Profitability
Adjusted gross profit increased to £3,728 million up 4.7% from £3,561 million in H1 2025, with adjusted gross margin expanding to 66.5%. Reported gross profit was £3,691 million, also up 4.7% year-on year.
Adjusted operating profit rose to £1,364 million, up 8.2% from £1,243 million in H1 2025. Adjusted operating margin improved to 24.3%, compared to 22.7% last year. Reported operating profit, however, declined to £1,172 million, down 2.6% from £1,203 million in H1 2025, impacted by restructuring costs.
Earnings
Adjusted diluted EPS climbed to 10.3p, up 12% from 9.2p in H1 2025. Reported diluted EPS fell to 8.5p, down 4.5% from 8.9p last year.
Cash Flow and Debt
Free cash flow improved to £769 million, compared to £734 million in H1 2025. Net cash flow from operating activities was £1,044 million, slightly higher than £1,027 million last year. Net debt/adjusted EBITDA stood at 2.5x in H1 2026, reflecting disciplined capital allocation.
Capital Allocation
Haleon announced approximately £240 million in capital investments for new manufacturing sites in China and India. The company completed £457 million of its planned £500 million share buyback program for 2026. An interim dividend of 2.4p per share was declared, up 9% from 2.2p in H1 2025.
Outlook
Haleon reaffirmed its FY 2026 guidance, expecting 3-5% organic revenue growth compared to £11,030 million achieved in FY2025 and high single-digit adjusted operating profit growth at constant currency.
Medium-term guidance remains at 4-6% annual organic revenue growth with continued gross margin expansion.
HLN.L has traded between £181.15 and £289.50 over the past year. The stock is currently trading at £228.30, down 9.01%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 30, 2026 04:24 ET The August 2026 FDA calendar features several important PDUFA decisions that could influence the biotech sector, healthcare innovation, and investor sentiment. In this video, we break down five major FDA decisions expected in August 2026, including the therapies, companies, and diseases under review:
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。